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Background. The treatment of secondary hyperparathyroidism
(2°HPT) associated with chronic renal failure adversely affects
skeletal growth.
Methods. We assessed epiphyseal growth plate morphology by
quantitative histology and measured mRNA levels for selected
markers of chondrocyte proliferation and differentiation by in situ
hybridization in the growth plate cartilage of subtotally nephrec-
tomized rats with either mild or advanced 2°HPT.
Results. The width of the growth plate cartilage in the proximal
tibia and mRNA levels for PTH/PTHrP receptor were unchanged
in rats with mild 2°HPT, however, they were markedly less in
nephrectomized rats with advanced 2°HPT than in intact controls.
Treatment with growth hormone 10 IU/kg/day increased growth
plate thickness both in mild and in advanced 2°HPT and raised
mRNA levels for type II and type X collagen in rats with advanced
2°HPT. The administration of calcitriol 50 ng/kg/day attenuated
these responses in animals with advanced 2°HPT. Overall, PTH/
PTHrP receptor mRNA levels did not correspond to the serum
levels of PTH indicating that PTH/PTHrP receptor expression is
down-regulated in renal failure by a PTH-independent mecha-
nism.
Conclusion. Calcitriol counteracts the trophic actions of growth
hormone on epiphyseal growth plate cartilage and modifies
chondrocyte differentiation in vivo, and these mechanisms may
contribute to disturbances in longitudinal bone growth in renal
failure.
Growth retardation is a major consequence of renal
failure in children. Several factors have been implicated in
the pathogenesis of this disorder, but tissue resistance to
the actions of growth hormone and/or insulin-like growth
factor I (IGF-I) and renal osteodystrophy due to secondary
hyperparathyroidism are generally considered to be the
most important contributors to impaired linear growth in
pediatric patients with established kidney disease [1, 2]. As
such, recombinant human growth hormone (rhGH) and
calcitriol, or 1,25-dihydroxyvitamin D3, are widely used to
prevent and/or treat growth retardation in children with
chronic renal failure [3, 4].
Growth hormone increases the rate of cell proliferation
both in chondrocytes and in osteoblast-like cells, enhances
collagen synthesis in vitro, promotes longitudinal bone
growth in experimental animals, and increases the thickness
of growth plate cartilage in normal and in uremic rats [5–7].
Accordingly, growth velocity increases during treatment
with rhGH in children with chronic renal failure and in
those who have undergone kidney transplantation [8]. In
contrast to these findings, calcitriol diminishes chondrocyte
proliferation in vitro, and it influences the differentiation of
chondrocytes within growth plate cartilage [9, 10]. Thus,
reductions in chondrocyte number and decreases in cellular
organization within epiphyseal cartilage have been re-
ported in neonatal mice given large doses of 1,25-dihy-
droxyvitamin D [10]. The importance of these findings is
underscored by the observation that treatment with large
intermittent doses of calcitriol diminishes linear growth in
pre-pubertal children undergoing regular dialysis [11].
Recent work has markedly increased our understanding
of the molecular mechanisms that regulate endochondral
bone formation during skeletal development. Parathyroid
hormone-related peptide (PTHrP), the receptor for PTH/
PTHrP and Indian hedgehog are integrally involved in the
control of chondrocyte differentiation within epiphyseal
cartilage [12], and as such, the PTH/PTHrP receptor plays
an important role in bone elongation and longitudinal
growth. Expression of the receptor for PTH/PTHrP in vitro
is affected by several hormonal agents including growth
hormone and 1,25-dihydroxyvitamin D, and it is reduced in
experimental animals with renal failure [13]. It is not
known, however, whether this abnormality contributes to
the growth retardation that characterizes chronic renal
disease. To investigate this issue, we assessed the separate
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and combined effects of growth hormone and calcitriol on
epiphyseal growth plate morphology, and measured mRNA
levels for selected molecular markers of endochondral
bone formation in the growth plate cartilage in rats with
renal failure and either mild or severe secondary hyper-
parathyroidism.
METHODS
Two separate experiments were done to assess the
responses to growth hormone and calcitriol in rats with
renal failure and different degrees of secondary hyperpara-
thyroidism.
Experiment #1 - Mild secondary hyperparathyroidism
Forty-five weanling male Sprague-Dawley rats (Harlan-
Sprague Dawley Laboratories, Indianapolis, IN, USA)
weighing 60 to 80 grams were studied. Animals were
housed in cages at constant temperature with a 12-hour
light-dark cycle; all had free access to food and drinking
water. After one week of acclimatization, 35 rats underwent
a two-stage 5/6 nephrectomy to induce renal failure as
previously described [14]. Anesthesia was achieved using
ketamine and xylazine. During the first stage nephrectomy,
approximately 2/3 of the left kidney was removed after
ligating both the upper and lower poles [14]. Seven days
later, the entire right kidney was removed after ligating the
vascular pedicle. Ten rats underwent sham nephrectomy in
two stages on the same days that actual nephrectomy
procedures were done. Sham nephrectomy involved a flank
incision with gentle manipulation of the kidney, but no
tissue was removed.
After both surgical procedures were completed, animals
were fed standard rat chow containing 23.4% protein, 0.6%
calcium and 0.68% phosphorus (Purina Mills, Indianapolis,
IN, USA). Rats with normal renal function were pair-fed
with animals who had undergone subtotal nephrectomy by
providing the amount of chow each day to intact rats that
had been consumed the previous day by nephrectomized
animals. Animals were weighed each week throughout the
experiment, and body length was determined weekly by
measuring from the tip of the nose to the end of the tail
while animals were sedated.
Four weeks after the second stage nephrectomy was
done, rats were begun on daily intraperitoneal (i.p.) injec-
tions of saline vehicle or hormonal agents; the duration of
treatment was 10 days. Ten intact control rats (C) and six
nephrectomized control rats (Nx-C) received vehicle only.
Five nephrectomized rats were given daily i.p injections of
rhGH (Nx-GH), 10 IU/kg/day (Pharmacia, Stockholm,
Sweden), whereas six nephrectomized rats received daily
i.p. injections of calcitriol (Nx-D), 50 ng/kg/day (Abbott
Laboratories, Chicago, IL, USA). An additional six ne-
phrectomized animals received daily doses of both rhGH
and calcitriol (Nx-GH1D).
After 10 days of treatment, rats were anesthetized with
ketamine and xylazine, and the animals were killed by
exsanguination by cardiac puncture; blood was saved for
subsequent biochemical determinations. Immediately after
death, tissues were fixed by transcardiac perfusion with 4%
paraformaldehyde in phosphate buffered saline (PFA/
PBS). Tibiae were excised, freed of adherent soft tissue and
immersed in 4% PFA/PBS for 48 hours. Bones were then
decalcified in 15% ethylenediamine tetra-acetic acid
(EDTA) in PBS, pH 7.0, at 4°C for two weeks. After
decalcification was complete, tibiae were washed in 10 mM
PBS for 24 hours, dehydrated in increasing concentrations
of ethanol and embedded in paraffin. Blocks were carefully
positioned to obtain frontal sections of tissue from the
proximal tibia with the plane of section oriented parallel to
the longitudinal axis of the bone. Separate five micrometer
sections of bone for morphometric analysis and for in situ
hybridization were obtained using a Jung-Reichert Model
1140 microtome (Warner Lambert, Buffalo, NY, USA),
and these were mounted on Superfrost Plus slides (Fisher
Scientific Co, Springfield, NJ, USA).
Experiment #2 - Severe secondary hyperparathyroidism
A total of fifty weanling male Sprague-Dawley rats
weighing 60 to 80 grams were prepared for study as
outlined in detail for Experiment #1. Ten rats underwent
sham nephrectomy and 40 rats underwent a two-stage 5/6
nephrectomy as previously described [14]. Rats with normal
renal function were given standard rat chow containing
23.4% protein, 0.6% calcium and 0.68% phosphorus (Pu-
rina Mills) as described in Experiment #1. Nephrecto-
mized animals received the same amounts of protein and
calcium, but the amount of phosphorus in the diet was
raised to 1.2% to increase the severity of secondary hyper-
parathyroidism [13]. Again, nephrectomized and intact
control rats were pair-fed and given free access to drinking
water throughout the experiment.
Four weeks after completing two-stage nephrectomies,
10 intact control rats (C) were started on daily i.p injections
of saline vehicle (C), and seven nephrectomized animals
also received daily vehicle injections (Nx-C). Seven ne-
phrectomized rats were treated with daily i.p injections of
rhGH (Nx-GH), 10 IU/kg/day, seven nephrectomized ani-
mals were given daily i.p. injections of calcitriol (Nx-D), 50
ng/kg/day and five nephrectomized rats received daily
injections of both hormones (Nx-GH1D). The doses of
growth hormone and calcitriol were the same as those used
in Experiment #1. Nephrectomized animals were assigned
at random to each treatment group.
After 10 days of treatment with either hormonal agents
or vehicle, the rats were killed as previously described.
Blood was obtained by cardiac puncture for subsequent
biochemical determinations, and tibiae were harvested
after perfusing the animals with 4% PFA/PBS.
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Serum biochemical determinations
After blood samples were obtained, serum was separated
by centrifugation, and these were stored at 270°C until
biochemical or hormonal assays were begun. Blood ionized
calcium levels were determined at the time of sacrifice
using a calcium sensitive electrode (ICA Radiometer,
Copenhagen, Denmark). Serum phosphorus, creatinine
and urea nitrogen levels were measured by standard labo-
ratory methods. Serum parathyroid hormone (PTH) levels
were measured using an immunoradiometric assay for rat
PTH (Immunotopics Inc, San Clemente, CA, USA).
Growth plate cartilage measurements
For morphometric analysis, four 5 mm sections of bone
were obtained from each tibia. These were mounted on
glass slides, stained with hematoxylin and eosin and coun-
terstained with azure A. The total width of the growth plate
cartilage at the proximal end of each tibia was measured at
equally spaced intervals using a digitizer tablet (Summa-
graphics, Seymour, CT, USA) connected to a microcom-
puter. A minimum of four width measurements was ob-
tained from each epiphyseal growth plate, and final width
determinations represent the average of these values. The
width of the zone occupied by hypertrophic chondrocytes
was measured by the same method. In addition to the
average width of the hypertrophic zone, the percentage of
the total width of the growth plate comprised of hypertro-
phic chondrocytes was also calculated. The extent of mar-
row fibrosis was graded on a scale ranging from 0 to 31 by
a single observer who had no knowledge about the exper-
imental procedures done on animals from whom specimens
had been collected.
In situ hybridization
In situ hybridization in sections of bone was done using
methods described in detail elsewhere [15]. Three speci-
mens from separate treatment groups were placed on single
glass slides to minimize slide-to-slide variation during pro-
cessing and development. Approximately 80 slides were
included in each hybridization using 35S-labeled riboprobes
encoding rat type II collagen, type X collagen and PTH/
PTHrP receptor. Riboprobes were generated using the
Gemini transcription kit (Promega, Madison, WI, USA).
Sense mRNA probes were used as negative controls. In situ
hybridization was completed using 1 3 106 cpm of 35S-
labeled (Amersham, Arlington Heights, IL, USA) type II
collagen mRNA, type X collagen mRNA and PTH/PTHrP
receptor mRNAs at 55°C overnight. After hybridization,
sections were washed with 5 3 SSC at 50°C, 50% form-
amide and 2 3 SSC at 50°C, 10 mM Tris-HCl with 500 mM
NaCl and 1 mM EDTA at 37°C, 2 3 SSC, 0.2 3 SSC and
increasing concentrations of ethanol. Slides were exposed
to X-ray film overnight (Fujifilm, Tokyo, Japan), and
emulsion autoradiography was done using NTB-2 (East-
man Kodak, New Haven, CT, USA) at 4°C. The length of
exposure was estimated from the intensity of the signals on
the X-ray film. The slides were developed and stained with
hematoxylin and eosin.
Quantitation of in situ hybridization signals
Slides were viewed at 3100 by bright field microscopy.
The images were captured using a CCD camera control
unit (Hamamatsu Photonics, Hamamatsu-City, Japan), and
these were displayed on a computer monitor. The number
of silver grains overlying each chondrocyte profile was
counted using an image analysis system (Kontron 200;
Kontron Elektronik, Germany). Twenty to 30 cell profiles
were assessed in each bone specimen, and the results for
individual bone samples represent the average of these
measurements. Data are expressed as the number of silver
grains/1000 mm2 of cell profile.
Statistical analysis
All results are expressed as means 6 one SD. Data were
evaluated using one-way analysis of variance with contrasts
[16]. Chi-square analysis was used to compare the extent of
marrow fibrosis among groups.
RESULTS
Experiment #1 - Mild secondary hyperparathyroidism
Neither total body wt at the end of study nor weight gain
during the 10-day experimental period differed among
groups (Table 1). Body length and the increase in length
during study also did not differ among groups (Table 1).
As expected, serum creatinine and blood urea nitrogen
(BUN) levels were higher in each group of nephrectomized
rats than in control animals with normal renal function,
whereas serum phosphorus values did not differ among
groups (Table 2). Serum PTH levels were moderately
higher in Nx-C than in C, but values were substantially
elevated in Nx-GH (Table 2). However, blood ionized
calcium concentrations did not differ among these three
groups. In contrast, serum PTH levels were substantially
lower and blood ionized calcium levels were higher both in
Table 1. Anthropometric measurements in rats with normal renal
function (Control) and in four groups of subtotally nephrectomized rats
with mild secondary hyperparathyroidism
Control
N 5 10
Nx-C
N 5 6
Nx-GH
N 5 5
Nx-D
N 5 6
Nx-GH1D
N 5 6
Weighta g 241 6 25 247 6 41 259 6 33 227 6 18 243 6 20
Gain in weightb g 11 6 25 17 6 18 25 6 8 210 6 30 6 6 34
Lengtha cm 38 6 0.1 38 6 1.6 38 6 1.9 37 6 0.6 38 6 1.1
Gain in lengthb
cm
7.9 6 0.9 8.1 6 1.8 8.0 6 1.7 7.5 6 0.5 8.1 6 0.1
Nephrectomized animals received daily intraperitoneal injections of
saline vehicle (Nx-C), growth hormone (Nx-GH), calcitriol (Nx-D) or both
hormonal agents together (Nx-GH1D) for 10 days.
a Obtained at the time of sacrifice
b Difference before and after 10 days of treatment
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nephrectomized rats given calcitriol (Nx-D) and in ne-
phrectomized animals given both growth hormone and
calcitriol (Nx-GH1D; Table 2).
The width of the growth plate cartilage did not differ
from control values in nephrectomized rats given vehicle
only (Fig. 1). Growth plate width was greater, however, in
Nx-GH than in either Nx-C or C (Fig. 1). There were no
differences in the width of the growth plate between Nx-D
and Nx-C, and the administration of calcitriol did not affect
the magnitude of the increase in growth plate thickness
after treatment with growth hormone in nephrectomized
rats with mild secondary hyperparathyroidism. Hence, the
growth plate width did not differ in Nx-GH1D and Nx-GH
(Fig. 1). Neither the width of the zone of hypertrophic
chondrocytes nor the ratio of the thickness of the hyper-
trophic zone to the total thickness of the growth plate
differed among the five study groups. None of the animals
with mild secondary hyperparathyroidism had histologic
evidence of marrow fibrosis.
The expression of mRNA for the PTH/PTHrP receptor
was localized to chondrocytes in the lower proliferating
zone and in the upper hypertrophic region. Type X colla-
gen mRNA was well localized to hypertrophic chondro-
cytes, whereas type II collagen transcripts were found both
in proliferating chondrocytes and in chondrocytes located
in the upper hypertrophic zone.
Expression of mRNAs for the PTH/PTHrP receptor and
for type II collagen did not differ among the four groups of
nephrectomized animals. Type X collagen mRNA expres-
sion was less, however, in Nx-C than in C (Fig. 2). Type X
collagen mRNA expression increased from values seen in
Nx-C both in Nx-GH and in Nx-D, and the levels of
expression in each of these two groups did not differ from
that in C (Fig. 2). Combined treatment with growth hor-
mone and calcitriol did not further increase type X collagen
mRNA expression from levels seen in Nx-GH or Nx-D.
Experiment #2 - Severe secondary hyperparathyroidism
Overall, body weight at the end of study and the increase
in body weight during each 10 day experiment were similar
in intact control animals in Experiments #1 and #2. In
nephrectomized rats with severe secondary hyperparathy-
roidism, the weight gain was less in Nx-C than in C (Table
3). Weight gain was somewhat greater in Nx-GH than in
Nx-C, but nephrectomized rats given calcitriol, either alone
or together with growth hormone, failed to gain weight
during the study. Neither total body length at the end of the
experiment nor the increase in body length differed among
groups (Table 3).
BUN and serum creatinine levels were greater in each
group of nephrectomized rats than in intact control ani-
mals, but values did not differ among Nx-C, Nx-GH, Nx-D
and Nx-GH1D (Table 4). Serum phosphorus levels were
also elevated in all four groups of nephrectomized rats
reflecting the higher dietary phosphorus content utilized in
Experiment #2 (Table 4). Serum PTH levels were mark-
edly elevated and blood ionized calcium concentrations
were substantially lower in Nx-C and in Nx-GH than in C;
however, the mean values did not differ between Nx-C and
Nx-GH (Table 4). Serum PTH levels were also elevated in
both groups of nephrectomized rats given calcitriol, but
PTH values were substantially lower and blood ionized
calcium concentrations were higher in Nx-D and Nx-
GH1D than in either Nx-C or Nx-GH (Table 4).
The width of the growth plate cartilage was moderately
reduced in Nx-C compared to C, and there was a decrease
in the organization of linear columns of proliferating and
hypertrophic chondrocytes in Nx-C compared to that seen
in intact control animals (Fig. 3). Treatment with rhGH not
only restored the micro-architecture of the growth plate,
but also increased its width. As such, the growth plate
thickness in Nx-GH exceed that in Nx-C, and values in
Nx-GH did not differ from those in C (Fig. 3). The
thickness of the growth plate cartilage did not differ
between Nx-D and Nx-C, but values were less in Nx-
GH1D than in Nx-GH. Thus, the growth plate width did
not differ between Nx-GH1D and Nx-C (Fig. 3). The width
of the zone of hypertrophic chondrocytes did not differ
among groups.
The amount of marrow fibrosis was greatest in Nx-GH,
whereas less marrow fibrosis was seen in Nx-C, Nx-D and
Nx-GH1D. Scores for marrow fibrosis, on a scale ranging
from 0 to 31, were 2.5, 1.0, 1.5 and 2.0, respectively, in
Nx-GH, Nx-C, Nx-D and Nx-GH1D (x2 5 16.6, P , 0.05).
In contrast to rats with mild secondary hyperparathyroid-
ism, PTH/PTHrP receptor expression was less in Nx-C than
in C; however, transcripts for PTH/PTHrP receptor were
again localized to chondrocytes in the lower proliferating
Table 2. Serum biochemical determinations at the end of study in rats
with normal renal function (Control) and in subtotally nephrectomized
animals with mild secondary hyperparathyroidism given daily injections
of saline vehicle (Nx-C), growth hormone (Nx-GH), calcitriol (Nx-D) or
both hormonal agents together (Nx-GH1D) for 10 days
Control
N 5 10
Nx-C
N 5 6
Nx-GH
N 5 5
Nx-D
N 5 6
Nx-GH1D
N 5 6
PTH pg/ml 82 6 24 111 6 69a 157 6 58b 6.0 6 2.0c,d 7.8 6 2.0c,d
Ionized
calcium
mmol/liter
1.3 6 0.02 1.3 6 0.03 1.3 6 0.04 1.5 6 0.09c,d 1.5 6 0.07c,d
Phosphorus
mg/dl
9 6 1.0 9 6 0.6 9 6 0.7 9 6 1.2 8 6 0.9
Creatinine
mg/dl
0.4 6 0.04 1.1 6 0.4a 1.1 6 0.34a 1.0 6 0.1a 1.3 6 0.4a
Urea
nitrogen
mg/dl
15 6 1 57 6 25a 57 6 22a 60 6 12a 61 6 18a
a P , 0.001 vs. Control
b P , 0.05 vs. Nx-C
c P , 0.001 vs. Nx-C
d P , 0.001 vs. Nx-GH
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zone and in the upper hypertrophic region (Fig. 4). Expres-
sion of mRNA for PTH/PTHrP receptor increased both in
Nx-GH and in Nx-D compared to Nx-C, and there were no
differences in PTH/PTHrP receptor mRNA expression
between Nx-GH and Nx-GH1D (Fig. 5). Neither type X
collagen nor type II collagen mRNA expression differed
between Nx-C and C, but mRNA transcripts for both type
X collagen and type II collagen were more abundant in the
growth plate cartilage in Nx-GH (Fig. 5). Expression of
mRNAs for both type X and type II collagens did not differ
in the Nx-GH1D from values determined in Nx-C.
DISCUSSION
The PTH/PTHrP receptor mediates the actions of two
distinct hormones: parathyroid hormone (PTH) and para-
thyroid hormone-related peptide (PTHrP) [12]. Its promi-
nent expression in bone and kidney accounts for the
well-established systemic calcium-regulating actions of
PTH, whereas its abundance in epiphyseal growth plate
cartilage mediates the localized actions of PTHrP on
chondrocyte proliferation and differentiation, thereby serv-
ing as an important regulator of skeletal modeling and
bone elongation [12]. Because PTH/PTHrP receptor ex-
pression is reduced in renal failure [13], the autocrine/
paracrine functions of PTHrP may be altered in this
disorder, and such changes could contribute to impair-
ments in linear growth. Moreover, since both calcitriol and
growth hormone modify PTH/PTHrP receptor expression
in vitro and because both hormonal agents are widely used
in the clinical management of children with growth retar-
dation due to chronic renal failure, we chose to examine the
impact of calcitriol and/or growth hormone administration
on markers of chondrocyte differentiation in the epiphyseal
growth plate cartilage of rats with renal failure and either
mild or advanced secondary hyperparathyroidism.
The results of the current investigation indicate that
differences in the severity of secondary hyperparathyroid-
ism affect not only epiphyseal growth plate morphology,
but also the expression of several molecular markers of
endochondral bone formation in experimental animals with
Fig. 1. The total width of the growth plate
cartilage (f) and the width of the hypertrophic
zone (M) in rats with normal renal function
(Control) and in four groups of subtotally
nephrectomized rats with mild secondary
hyperparathyroidism. Nephrectomized animals
received daily intraperitoneal injections of
saline vehicle (Nx-C), growth hormone (Nx-
GH), calcitriol (Nx-D), or both hormonal
agents together (Nx-GH1D) for 10 days. aP ,
0.001 vs. Nx-C; bP , 0.001 vs. Nx-GH; cP ,
0.001 vs. Nx-D.
Fig. 2. Type X collagen mRNA expression in the growth plate cartilage in
rats with normal renal function (Control) and in four groups of subtotally
nephrectomized rats with mild secondary hyperparathyroidism. Nephrec-
tomized animals received daily intraperitoneal injections of saline vehicle
(Nx-C), growth hormone (Nx-GH), calcitriol (Nx-D), or both hormonal
agents together (Nx-GH1D) for 10 days. aP , 0.001 vs. Control; bP ,
0.001 vs. Nx-C; cP , 0.005 vs. Nx-C; dP , 0.01 vs. Nx-C; eP , 0.001 vs.
Nx-D.
Table 3. Anthropometric measurements in rats with normal renal
function (Control) and in four groups of subtotally nephrectomized rats
with advanced secondary hyperparathyroidism
Control
N 5 10
Nx-C
N 5 7
Nx-GH
N 5 7
Nx-D
N 5 7
Nx-GH1D
N 5 5
Weighta g 231 6 18 207 6 43 220 6 40 203 6 33 203 6 42
Gain in
weightb g
14 6 15 1.2 6 10c 20.3 6 13d 25.8 6 16e,f 21.6 6 18e,f
Lengtha cm 37 6 1.0 36 6 1.0 37 6 2.0 36 6 1.0 36 6 2.0
Gain in lengthb
cm
6.5 6 0.4 5.7 6 2.3 6.3 6 2.3 5.5 6 1.8 5.2 6 2.3
Nephrectomized animals received daily intraperitoneal injections of
saline vehicle (Nx-C), growth hormone (Nx-GH), calcitriol (Nx-D) or both
hormonal agents together (Nx-GH1D) for 10 days.
a Obtained at the time of sacrifice
b Difference before and after 10 days of treatment
c P , 0.05 vs. Control
d P , 0.005 vs. Nx-C
e P , 0.001 vs. Nx-C
f P , 0.001 vs. Nx-GH
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renal failure. Growth plate thickness was reduced and
PTH/PTHrP receptor mRNA levels were diminished in
nephrectomized rats with advanced secondary hyperpara-
thyroidism, but neither change was evident in animals with
mild secondary hyperparathyroidism. Calcitriol blunted the
trophic effect of growth hormone on epiphyseal growth
plate thickness in rats with advanced secondary hyperpara-
thyroidism, and this disturbance was associated with reduc-
tions in growth hormone-induced increases in mRNAs for
both type X and type II collagen. In contrast, calcitriol did
not attenuate the increase in growth plate thickness asso-
ciated with growth hormone administration in rats with
mild secondary hyperparathyroidism. Calcitriol also did not
affect the rise in PTH/PTHrP receptor mRNA expression
following growth hormone administration in nephrecto-
mized rats with either mild or advanced secondary hyper-
parathyroidism despite substantial differences in basal
PTH/PTHrP receptor mRNA levels in growth plate chon-
drocytes. Although the changes need to be confirmed by
immunohistochemical techniques, the current results sug-
gest that the severity of secondary hyperparathyroidism can
modify the expression of key regulators of endochondral
bone formation and longitudinal bone growth in rats with
renal failure, and that 1,25-dihydroxyvitamin D influences
the in vivo response to exogenous growth hormone in this
experimental model.
The thickness of epiphyseal growth plate cartilage was
diminished in untreated nephrectomized rats with severe
secondary hyperparathyroidism, but similar reductions
could not be documented in rats with mild secondary
hyperparathyroidism. Despite these differences, the admin-
istration of exogenous growth hormone increased growth
plate thickness not only in animals with mild secondary
hyperparathyroidism but also in those with severe second-
ary hyperparathyroidism. Such findings are consistent with
results reported previously by Mehls and colleagues [7]. In
contrast, Hanna et al noted that only the width of the zone
of hypertrophic chondrocytes increased in rats treated with
growth hormone, whereas the overall width of the epiphy-
seal cartilage did not change [17]. Others have also failed to
document increases in growth plate thickness during treat-
ment with growth hormone despite increases in the number
of proliferating chondrocytes in epiphyseal cartilage [18,
19]. The explanation for these divergent findings remains
uncertain, but the presence and/or the severity of secondary
hyperparathyroidism may be a contributing factor. Since
the mitogenic actions of parathyroid hormone on growth
plate chondrocytes are mediated, at least in part, by IGF-I
[20], PTH-dependent changes in basal IGF-I levels locally
within epiphyseal cartilage may serve to augment the IGF-I
mediated actions of growth hormone in proliferating chon-
drocytes in rats with markedly elevated serum PTH levels.
Several reports have implicated PTH as a potential
modifier of the actions of growth hormone in skeletal
tissues [20, 21]. Although serum PTH levels were not
measured, Berger and co-workers found that linear growth
was less in growth hormone-treated rats given intermittent
doses of calcitriol, which would be expected to lower serum
PTH levels, than in animals receiving growth hormone
alone [22]. More recently, Kuizon et al reported that
pre-pubertal children undergoing regular peritoneal dialy-
sis with relatively low serum PTH levels and adynamic renal
osteodystrophy grew less well than subjects of the same age
and pubertal status with overt secondary hyperparathyroid-
ism [11]. Indeed, changes in Z-scores for height over 12
months correlated directly with serum PTH levels. Al-
though such findings suggest that PTH can modify the
skeletal response to growth hormone as judged by changes
in linear growth, direct inhibitory effects of calcitriol on
chondrocyte proliferation and/or differentiation could also
explain these results.
In the current study, mRNA levels for the PTH/PTHrP
receptor were reduced in the growth plate chondrocytes of
nephrectomized rats with severe secondary hyperparathy-
roidism but not in those with mild disease, indicating that
the severity of secondary hyperparathyroidism may be an
important determinant of PTH/PTHrP receptor expression
in rats with renal failure. Such findings differ from those
reported by Uren˜a and co-workers, who found that PTH/
PTHrP receptor expression in the kidney, as assessed by
immunohistochemistry, was similarly reduced both in para-
thyroidectomized and in intact rats with renal failure [23].
Previous studies have not, however, assessed PTH/PTHrP
receptor mRNA levels in the growth plate cartilage of
animals with varying degrees of secondary hyperparathy-
roidism. Given the crucial role of PTHrP and its receptor as
regulators of chondrocyte differentiation during endochon-
dral bone growth, differences in basal PTH/PTHrP recep-
tor expression between mild and advanced secondary hy-
perparathyroidism could account for variations in the
trophic effect of growth hormone on epiphyseal growth
Table 4. Serum biochemical determinations at the end of study in rats
with normal renal function (Control) and in subtotally nephrectomized
animals with advanced secondary hyperparathyroidism given daily
injections of saline vehicle (Nx-C), growth hormone (Nx-GH), calcitriol
(Nx-D) or both hormonal agents together (Nx-GH1D) for 10 days
Control
N 5 10
Nx-C
N 5 7
Nx-GH
N 5 7
Nx-D
N 5 7
Nx-GH1D
N 5 5
PTH pg/ml 84 6 22 557 6 157a 619 6 84 342 6 289b,c 348 6 264b,c
Ionized
calcium
mmol/L
1.3 6 0.01 0.9 6 0.18a 1.0 6 0.18 1.3 6 0.05b,c 1.2 6 0.17b,c
Phosphorus
mg/dl
8 6 0.3 15 6 5.0a 16 6 0.3a 13 6 4.5a 16 6 8.6a
Creatinine
mg/dl
0.3 6 0.51 1.3 6 0.51a 1.0 6 0.33a 0.9 6 0.34a 1.0 6 0.32a
Urea
nitrogen
mg/dl
14 6 2.0 103 6 57a 81 6 42a 74 6 44a 96 6 56a
a P , 0.01 vs. Control
b P , 0.005 vs. Nx-C
c P , 0.001 vs. Nx-GH
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plate cartilage in these two disorders. Indeed, the effect of
calcitriol to blunt growth hormone-induced increases in
growth plate thickness and mRNA levels for both type II
and type X collagen in rats with advanced secondary
hyperparathyroidism without modifying the growth hor-
mone-associated rise in mRNA expression for the PTH/
PTHrP receptor levels suggests that calcitriol can directly
affect chondrocyte proliferation and/or differentiation by
mechanisms separate from those mediated by PTHrP and
its receptor.
Previous in vitro studies have demonstrated dose-depen-
dent inhibitory effects of calcitriol on cell proliferation and
DNA synthesis in chondrocytes [9, 10]. Silbermann and
co-workers reported that doses of calcitriol exceeding 50
ng/kg/day in the rat reduced the heights of the zones of
proliferating and hypertrophic chondrocytes in epiphyseal
cartilage, and growth retardation was evident after only
seven days of treatment with large doses of calcitriol [10].
The mechanisms responsible for these inhibitory effects of
calcitriol remain uncertain, but Scharla et al suggested that
the blunted response to growth hormone during calcitriol
therapy might be explained by reductions in local IGF-I
Fig. 3. The total width of the growth plate
cartilage (f) and the width of the hypertrophic
zone (M) in rats with normal renal function
(Control) and in four groups of subtotally
nephrectomized rats with advanced secondary
hyperparathyroidism. Nephrectomized animals
received daily intraperitoneal injections of
saline vehicle (Nx-C), growth hormone (Nx-
GH), calcitriol (Nx-D), or both hormonal
agents together (Nx-GH1D) for 10 days. aP ,
0.001 vs. Control; bP , 0.001 vs. Nx-C; cP ,
0.005 vs. Nx-GH
Fig. 4. PTH/PTHrP receptor mRNA expression was localized to chondrocytes in the lower proliferating zone and in the upper hypertrophic region of
the growth plate cartilage in rats with normal renal function (A) and in four groups of subtotally nephrectomized rats with advanced secondary
hyperparathyroidism. Nephrectomized animals received daily intraperitoneal injections of saline vehicle (B), growth hormone (C), calcitriol (D), or both
hormonal agents together (E) for 10 days. The expression of PTH/PTHrP receptor mRNA was markedly less in the nephrectomized animals given saline
injections (B) compared to rats with normal renal function (A), however, the transcripts for PTH/PTHrP receptor were increased in animals given
growth hormone (C), calcitriol (D) and both hormonal agents together (E) compared to nephrectomized control animals (B).
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production and/or by increases in the amount of the
inhibitory IGF binding protein IGF-BP-4 [24]. In this
regard, neither the addition of growth hormone nor IGF-I
to the culture medium could overcome the suppressive
effect of calcitriol on cell proliferation in chondrocytes and
osteoblast-like cells [25]. Additional work will be required
to determine whether similar mechanisms explain the in
vivo inhibitory actions of calcitriol on epiphyseal growth
thickness in rats with severe secondary hyperparathyroid-
ism.
PTH/PTHrP receptor mRNA levels failed to correspond
to the prevailing concentration of PTH in serum in the
current series of experiments. Therefore, PTH/PTHrP re-
ceptor mRNA levels were markedly greater in rats given
growth hormone than in untreated nephrectomized ani-
mals with advanced secondary hyperparathyroidism,
whereas serum PTH levels did not differ between these two
experimental groups. Similarly, the concurrent administra-
tion of calcitriol and growth hormone to rats with severe
secondary hyperparathyroidism did not alter PTH/PTHrP
receptor mRNA expression compared to values seen in rats
given growth hormone alone, but serum PTH levels were
markedly lower in calcitriol-treated animals. Such findings
indicate that growth hormone and calcitriol can each affect
PTH/PTHrP receptor message expression in growth plate
chondrocytes in vivo by mechanisms that are not dependent
on the concentration of PTH in serum. The current results
are consistent, therefore, with previous work indicating that
elevated serum PTH levels are not required for down-
regulation of PTH/PTHrP receptor expression in the kid-
ney of rats with renal failure [23].
Considerable evidence indicates that PTHrP and its
receptor together with at least one of the hedgehog pro-
teins, that is, Indian hedgehog, participate in the regulation
of chondrocyte differentiation in epiphyseal cartilage dur-
ing endochondral bone formation [12]. Mice in which both
alleles of the gene encoding PTHrP have been deleted
exhibit marked skeletal abnormalities characterized by
shortened limbs, premature skeletal mineralization and
early closure of the epiphyses of long bones [26]. Such
changes result from the premature differentiation of pro-
liferating chondrocytes into hypertrophic chondrocytes
leading to early cessation of linear growth, and they are
associated with increases in type X collagen expression
which is generally considered to be a phenotypic marker for
hypertrophic chondrocytes.
In the current study, the administration of growth hor-
mone to nephrectomized rats with severe secondary hyper-
parathyroidism increased mRNA expression for type X
collagen, but mRNA levels for type II collagen also in-
creased. Calcitriol diminished the magnitude of these re-
sponses in association with lesser changes in growth plate
thickness during growth hormone treatment. Such findings
suggest that growth hormone increases the rate of cell
proliferation in proliferating chondrocytes and that it may
also promote the expression of a more differentiated
phenotype in hypertrophic chondrocytes. In contrast, cal-
citriol appears to offset the trophic effects of growth
hormone on chondrocyte proliferation in epiphyseal carti-
lage as judged by measurements of growth plate thickness,
and this mode of action may contribute to reductions in
growth plate thickness and in longitudinal bone growth
Fig. 5. Type X collagen mRNA, type II collagen mRNA and PTH/PTHrP receptor mRNA expression in the growth plate cartilage in rats with normal
renal function (Control; M) and in four groups of subtotally nephrectomized rats with advanced secondary hyperparathyroidism. Nephrectomized
animals received daily intraperitoneal injections of saline vehicle (Nx-C; f), growth hormone (Nx-GH; z), calcitriol (Nx-D; s), or both hormonal agents
together (Nx-GH1D; o) for 10 days. aP , 0.05 vs. Control; bP , 0.001 vs. Nx-C; cP , 0.05 vs. Nx-C; dP , 0.05 vs. Nx-GH; eP , 0.001 vs. Nx-GH.
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during treatment with calcitriol in rats with advanced
secondary hyperparathyroidism due to chronic renal fail-
ure. The precise effect of calcitriol on the differentiation of
proliferating cells into hypertrophic chondrocytes in vivo
remains less certain, however, since the widely recognized
actions of calcitriol to promote cellular differentiation
would have been expected to increase rather than decrease
type X collagen expression in the current experiment.
Additional work will be required to clarify this matter.
In summary, the results of the current investigation
indicate that both growth hormone and calcitriol influence
the proliferation and differentiation of epiphyseal growth
plate chondrocytes in rats with secondary hyperparathy-
roidism due to chronic renal failure. Calcitriol blunts the
trophic actions of growth hormone on epiphyseal growth
plate thickness and on type X and type II collagen expres-
sion by chondrocytes without modifying mRNA levels for
PTH/PTHrP receptor. Such actions may contribute to
impaired skeletal growth in pre-pubertal children with
end-stage renal disease who are treated with large doses of
calcitriol, and they may also account for the variable clinical
response to growth hormone administration in pediatric
patients with chronic renal disease.
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